NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Capital Markets · USD

DNA X, Inc. (SONM) Stock Analysis

DNA X, Inc. (SONM) is a Capital Markets stock listed on NASDAQ and quoted in US Dollar.

SONM

$3.24

+$0.02 (+0.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SONM with… →

SONM Key Statistics

As of Sep 4, 2026
Trading
Open
$3.20
Previous Close
$3.22
Day's Range
3.12–3.47
52-Week Range
2.52–16.97
Volume
19.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.86
Valuation
Market Cap
$4.82M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.86
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.34
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$20.66M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.49M
1-Year Return
−69.59%
Dividend and dates
Avg Volume
21.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SONM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.86%
2025−94.45%
2024−57.07%
2023+72.94%
2022−53.90%
2021−87.27%
2020−80.06%
2019 (partial year)−66.97%

As of September 4, 2026.

SONM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$20.66M—
2024$0.00−$33.65M—
2023$93.63M−$90.00K−0.1%
2022$69.83M−$14.09M−20.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$5.41M−$20.66M—
2024$0.00$0.00−$3.10M−$33.65M—
2023$93.63M$19.32M$513.00K−$90.00K−0.1%
2022$69.83M$11.62M−$14.29M−$14.09M−20.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SONM Valuation vs Capital Markets Median

Median of 106 stocks
MetricSONMCapital Markets medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 106 Capital Markets stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

DNA X, Inc. (SONM) is capitalised at $4.82M on the latest close. It is classified in the Capital Markets industry, within the Financial Services sector. The company reports 4 employees.

Over the past 52 weeks the price has ranged from $2.52 to $16.97. SONM last closed at $3.24 on September 4, 2026. That is +$0.02 (+0.68%) against the previous close. The latest close sits 28.52% above that 52-week low.

Financial Health

In fiscal 2025, DNA X, Inc. reported revenue of $0.00. The same year closed with a net loss of $20.66M. The reported profit margin is 0%. Trailing earnings per share are −8.34.

Across the 4 fiscal years on file, revenue moves from $69.83M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 3.86. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.25.

The trailing one-year price return is −69.59%. Measured over 5 years, that is −66.88% a year compounded. Beta against the wider market is reported at 1.86. Daily returns over the trailing 7 years annualize to a volatility of 117.12%.

Growth & Income

No dividend is on file for SONM.

The strongest complete calendar year on file is 2023 at +72.94%; the weakest is 2025 at −94.45%. Of the 6 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +2.86% year to date.

Peer Comparison

DNA X, Inc. (SONM) operates in the Capital Markets industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
DNA X, Inc. SONM $4.82M —
Morgan Stanley MS $341.94B 17.5
The Goldman Sachs Group, Inc. GS $302.41B 16.0
The Charles Schwab Corporation SCHW $189.00B 19.9

The Capital Markets industry average P/E ratio is 16.4x. DNA X, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Capital Markets Stocks

MS

Morgan Stanley

$341.94B

 GS

The Goldman Sachs Group, Inc.

$302.41B

 SCHW

The Charles Schwab Corporation

$189.00B

 IBKR

Interactive Brokers Group, Inc.

$157.81B

 HOOD

Robinhood Markets, Inc.

$109.79B

 NMR

Nomura Holdings, Inc.

$31.13B
View all Capital Markets stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

 JPM

JPMorgan Chase & Co.

$953.33B

 V

Visa Inc.

$700.27B

 MA

Mastercard Incorporated

$507.39B

 BAC

Bank of America Corporation

$438.31B
View all Financial Services stocks →

About DNA X, Inc.

DNA X, Inc. provides cryptocurrency trading services worldwide. The company operates a cryptocurrency trading platform that allows users to trade and swap cryptocurrencies for other cryptocurrencies or cash-equivalent currencies. It markets its services through word of mouth and earned media on social media platforms. The company serves individual cryptocurrency traders. The company was formerly known as Sonim Technologies, Inc. and changed its name to DNA X, Inc. in January 2026. DNA X, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Visit website →